Sleep and Immune Response in Severe Obese Patients Undergoing Bariatric Surgery.

Morbid Obesity Clinical Trial

Official title:

Sleep, Pulmonary Function, Systemic and Adipose Immune Response and Quality of Life in Severe Obese Patients Undergoing Bariatric Surgery. A Protocol of Randomized Controlled Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02409160
• Other study ID #: 220506/2009
• Status: Recruiting
• Phase: N/A
• Start date: March 2015
• Est. completion date: July 2019

Study information

• Verified date: May 2018
• Source: Centro Universitário de Anapolis
• Contact: Luis VF Oliveira, PhD
• Phone: +55 11 991702292
• Email: oliveira.lvf[@]pq.cnpq.br
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Obesity is a major public health problem in developed and developing countries, causing a range of respiratory and metabolic changes. There is a strong correlation between obesity and cardiorespiratory sleep disorders. The weight loss reduces the comorbidities and improves the quality of life, but clinical treatment it is not effective for a long period. In this context, currently bariatric surgery is an option for the real weight loss in the long term. Obstructive sleep apnea (OSA) is a common clinical condition observed in patients with obesity. The primary aim of this protocol are to assess the inflammatory profile of severe obese patients undergone to bariatric surgery, through systemic and adipose markers of inflammation. A secondary objective is study the impact of this surgery on sleep variables and quality of life. Investigators hypothesized that weight loss induced by bariatric surgery reduces systemic inflammatory profile, improve sleep quality and quality of life of subjects with severe obesity. Will participate in this study, patients with severe obesity (BMI > 40 or 35 to 39.9 kg/m2 associated comorbidities), with indication of bariatric surgery, screened Bariatric Surgery Service of Santa Casa de São Paulo in São Paulo. Inclusion criteria are severely obese, bariatric surgery indication and agreement to participate in the study. Are excluded patients with BMI > 55 kg/m2, clinical instability, mental instability or significant and unrealistic expectations of surgery. Patients will be assessed before and after bariatric surgery, 90, 180 and 360 days. The evaluation protocol will consist of clinical history, vital signs, neck and waist circumference, clinical analysis of blood inflammatory markers, lung function tests, maximal ventilatory pressures, full overnight standard polysomnography, excessive daytime sleepiness scale, cardiovascular risk, quality of life and personal satisfaction questionnaires.

Description:

Obesity is a major public health problem in developed and developing countries, causing a range of respiratory and metabolic changes. There is a strong correlation between obesity and cardiorespiratory sleep disorders. The weight loss reduces the comorbidities and improves the quality of life, but clinical treatment it is not effective for a long period. In this context, currently bariatric surgery is an option for the real weight loss in the long term. Obstructive sleep apnea (OSA) is a common clinical condition observed in patients with obesity. Recent studies have found that more than 2/3 of obese patients also have OSA, and that these exhibit similar pathophysiological substrates for cardiovascular disease where increased blood pressure is a common consequence. This raises another discussion where obesity and OSA may have an additive effect on cardiovascular risk factors. Our main objective is to evaluate whether the systemic and adipose markers of inflammation alters after bariatric surgery through biochemical indexes in the visceral (omental, mesenteric) and subcutaneous adipose tissue depots and fasting blood samples, including the proinflammatory cytokines tumor necrosis factor α (TNFα), interleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 18 (IL-18), soluble TNF receptor-2 (sTNFR2), soluble E-selectin, soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), monocyte chemoattractant protein 1 (MCP 1), high sensitivity C-reactive protein (hsCRP), adiponectin (AdipoQ) genes, vascular endothelial growth factor A (VEGF-A), nuclear factor Kappa B (NF-kB) and adipose-derived hormone leptin. Moreover, identify the possible association of systemic and adipose inflammation before bariatric surgery with the magnitude of surgery-induced weight loss and to assess pulmonary function through spirometry and, maximal ventilatory pressures through vacuometry; to determine whether surgical procedure induced decrease in body weight, BMI, abdominal circumference and, improve quality of life; to study sleep patterns through full standard polysomnography and quality of life in obese patients undergone to bariatric surgery and verify a possible correlation between weight loss and physiological variables. Will participate in this study, patients with severe obesity (BMI > 40 or 35 to 39.9 kg/m2 associated comorbidities), with indication of bariatric surgery, screened Bariatric Surgery Service of Santa Casa de São Paulo in São Paulo. Inclusion criteria are severely obese, bariatric surgery indication and agreement to participate in the study. Are excluded patients with BMI > 55 kg/m2, clinical instability, mental instability or significant and unrealistic expectations of surgery. Patients will be assessed before and after bariatric surgery, 90, 180 and 360 days. The evaluation protocol will consist of clinical history, vital signs, neck and waist circumference, clinical analysis of blood inflammatory markers, lung function tests, maximal ventilatory pressures, full overnight standard polysomnography, excessive daytime sleepiness scale, cardiovascular risk, quality of life and personal satisfaction questionnaires.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 17
• Est. completion date: July 2019
• Est. primary completion date: July 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Patients eligible for the trial must comply with all of the following at randomization:

2. male and female patients aged 18 to 65 years,

3. grade III severe obesity (BMI = 40 kg/m2) or = 35 kg/m2 with comorbidities,

4. awaiting bariatric surgery,

5. with documented history of conventional weight loss attempts having proven unsuccessful over time,

6. and if they are able to understand and agreement to participate in the study through a signed term of informed consent.

Exclusion Criteria:

1. Any medical condition rendering surgery too risky;

2. BMI above 55 kg/m2;

3. Unrealistic postoperative target weight and/or unrealistic expectations of surgical treatment;

4. Pregnancy, lactation or planned pregnancy within two years of potential surgical treatment;

5. Lack of safe access to abdominal cavity or gastrointestinal tract;

6. Abusive alcohol use or drug use.

7. Cancer

8. Any cardiorespiratory condition opposite indicate the surgical procedure.

Related Conditions & MeSH terms

• Morbid Obesity
• Obesity
• Obesity, Morbid
• Severe Obesity

Intervention

Procedure:
• Standard Roux-en-Y gastric bypass

Locations

Country	Name	City	State
Brazil	Centro Universitário de Anápolis - UniEVANGÉLICA	Anápolis	GO
Brazil	Gastromed	Anápolis	GO
Brazil	Department of Surgery of Santa Casa of São Paulo Medical School, Gastric Surgery Division	Sao Paulo	SP

Sponsors (4)

Lead Sponsor	Collaborator
Centro Universitário de Anapolis	Clínica de Gastroenterologia e Medicina Avançada - GASTROMED, Irmandade da Santa Casa de Misericordia de Sao Paulo, Santa Casa de Misericórdia de Anápolis

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in systemic immune response after bariatric surgery.	Systemic markers of inflammation through fasting blood samples biochemical indexes.	Baseline immune response to 180 days.
Primary	Change in systemic adipose inflammation response after bariatric surgery.	Systemic markers of inflammation through biochemical indexes in the visceral (omental, mesenteric) and subcutaneous adipose tissue depots.	Baseline adipose inflammation response to 180 days.
Secondary	Alterations in sleep quality after bariatric surgery.	Study sleep patterns through full standard polysomnography.	180 days
Secondary	Changes in pulmonary function after bariatric surgery.	Assess pulmonary function through spirometry.	180 days
Secondary	Changes in maximal ventilatory pressures after bariatric surgery.	Assess maximal inspiratory and expiratory pressures through vacuometry.	180 days
Secondary	Changes in health related quality of life after bariatric surgery.	Changes in quality of life through Short Form-36 and BAROS questionnaires.	180 days